Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.37 |
| ▸ | RAB9A | P51151 | 9/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.32 |
| ▸ | MEN1 | O00255 | 9/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 4/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 3/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822990 | 0.79 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1819297 | 0.69 | KDM1A (0.35) | NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL3340590 | 0.65 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3340846 | 0.65 | GAA (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4960018 | 0.64 | — | — | |
| Iodide SCHEMBL3991507 | 0.62 | — | — | |
| Fumaric Acid SCHEMBL9048088 | 0.60 | — | — | |
| Fumaric Acid SCHEMBL9045625 | 0.59 | — | — | |
| Fumaric Acid SCHEMBL9047183 | 0.59 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8628158 | 0.58 | NPSR1 (0.42) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407977-B2 | Substituted N-acyl-2-aminothiazoles | HOFFMAN-LA ROCHE INC. (US) | 2008-08-05 | — | — | US | claimed |
| EP-1791822-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-06 | — | — | EP | claimed |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | HOFFMANN-LA ROCHE INC. | 2006-02-09 | — | — | US | claimed |
| WO-2006013054-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | claimed |
| US-7407977-B2 | Substituted N-acyl-2-aminothiazoles | HOFFMAN-LA ROCHE INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1791822-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | HOFFMANN-LA ROCHE INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2006013054-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | SLC5A2, ABAT, AGTR2 | NPC1 1402/4885RAB9A 1576/4885SMN1; SMN2 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.